** Shares of Sun Pharmaceutical Industries SUN.NS gains ~1.1% in March, marking second straight month of gains
** Stock among four Nifty 50 .NSEI constituents to log a monthly gain in a weak broader market
** Analysts expect the pharma co to benefit from the launch of weight-loss drugs in India
** UBS estimates generic GLP-1 market opportunity to reach $7.6 billion by 2030 for Indian pharma companies and says co is best placed to capture this long-term opportunity
** Stock rated "buy" on avg; median PT 1,978 rupees - data compiled by LSEG
** Stock up 2.1% YTD, closes 2% lower on Monday
nifty50 https://tmsnrt.rs/4sCF4jF
(Reporting by Aleef Jahan in Bengaluru)
((aleefjahan.cs@thomsonreuters.com))